Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial

Journal of the American Society of Nephrology

Volumn 17, Issue 5, 2006, Pages 1444-1452

  Ishani, Areef ^a,b   Grandits, Greg A ^b   Grimm, Richard H ^c   Svendsen, Kenneth H ^b   Collins, Allan J ^d   Prineas, Ronald J ^e   Neaton, James D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Berman Center for Outcomes and Clinical Research   (United States)

^d United States Renal Data System   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIPSTICK ANALYSIS; FASTING BLOOD GLUCOSE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL INFORMATION SYSTEM; MULTIPLE RISK FACTOR INTERVENTION TRIAL; NATIONAL DEATH INDEX; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; RISK FACTOR; UNITED STATES; UNITED STATES RENAL DATA SYSTEM; URINALYSIS; VITAL STATISTICS;

EID: 33646343461     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005091012     Document Type: Article

References (35)

1. US Renal Data System: USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, US Renal Data System, 2000
2. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK: Progression rate to end-stage renal failure in non-diabetic kidney diseases: A multivariate analysis of determinant factors. Nephrol Dial Transplant 10: 1353-1360, 1995
3. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002
4. Keane WF, Brenner BM, De Zeeuw D, Grunfeld JP, Mcgill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 63: 1499-1507, 2003
5. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A: Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 11: 461-467, 1996
6. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762, 1995
7. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ: Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278: 2069-2074, 1997
8. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14: 2934-2941, 2003
9. Iseki K, Iseki C, Ikemiya Y, Fukiyama K: Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 49: 800-805, 1996
10. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25: 587-594, 1995
11. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 277: 1293-1298, 1997
12. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41: 1341-1345, 2003
13. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334: 13-18, 1996
14. Neaton JD, Grimm RH, Cutler JA: Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). Control Clin Trials 8[Suppl]: 41S-53S, 1988
15. Sherwin R, Kaelber CT, Kezdi P, Kjelsberg MO, Thomas HE Jr: The Multiple Risk Factor Intervention Trial (MRFIT) II. The development of the protocol. Prev Med 10: 402-425, 1981
16. Eberly LE, Neaton JD, Thomas AJ, Yu D: Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial. Clin Trials 1: 148-161, 2004
17. Widdowson GM, Kuehneman M, DuChene AG, Hulley SB, Cooper GR: Quality control of biochemical data in the multiple risk factor intervention trial: Central laboratory. Control Clin Trials 7: 17-33, 1986
18. Dischinger P, DuChene AG: Quality control aspects of blood pressure measurements in the Multiple Risk Factor Intervention Trial. Control Clin Trials 7[Suppl]: 137S-157S, 1986
19. US Renal Data System: Researcher's Guide to the USRDS Database, Bethesda, US Renal Data System, 2002
20. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS: The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 142: 342-351, 2005
21. Wentworth DN, Neaton JD, Rasmussen WL: An evaluation of the Social Security Administration master beneficiary record file and the National Death Index in the ascertainment of vital status. Am J Public Health 73:1270-1274, 1983
22. Cox DR: Regression models and life tables with discussion. J R Stat Soc (B) 34: 187-220, 1972
23. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-266, 2002
24. Kannel WB, Stampfer MJ, Castelli WP, Verier J: The prognostic significance of proteinuria: The Framingham study. Am Heart J 108: 1347-1352, 1984
25. Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G: Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl 63: S54-S57, 1997
26. Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63: 1468-1474, 2003
27. Burton C, Harris KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27: 765-775, 1996
28. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, De Jong PE, De Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140, 2001
29. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309-2320, 2004
30. Iseki K, Ikemiya Y, Iseki C, Takishita S: Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 18: 899-905, 2003
31. World Health Organization: Nutritional Anaemias: Report of a WHO Scientific Group, Geneva, World Health Organization, 1968
32. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA: Surrogate markers for cardiovascular disease: Functional markers. Circulation 109: IV31-IV46, 2004
33. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004
34. Al Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955-962, 2001
35. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004